Comments
Loading...

Veracyte Analyst Ratings

VCYTNASDAQ
Logo brought to you by Benzinga Data
Q1 2025 Earnings in 13 days from now on Wed May 7th, after the market close
Consensus Rating1
Buy
Highest Price Target1
$51.00
Lowest Price Target1
$28.00
Consensus Price Target1
$41.10

Veracyte Analyst Ratings and Price Targets | NASDAQ:VCYT | Benzinga

Veracyte Inc has a consensus price target of $41.1 based on the ratings of 11 analysts. The high is $51 issued by Needham on February 25, 2025. The low is $28 issued by Morgan Stanley on November 18, 2024. The 3 most-recent analyst ratings were released by Guggenheim, Stephens & Co., and Craig-Hallum on April 9, 2025, March 26, 2025, and March 20, 2025, respectively. With an average price target of $42.33 between Guggenheim, Stephens & Co., and Craig-Hallum, there's an implied 32.62% upside for Veracyte Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Jan
3
Feb
2
Mar
1
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.5
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Guggenheim
Stephens & Co.
Craig-Hallum
UBS
Needham

1calculated from analyst ratings

Analyst Ratings for Veracyte

Buy NowGet Alert
04/09/2025Buy Now15.91%Guggenheim
Subbu Nambi35%
$45 → $37MaintainsBuyGet Alert
03/26/2025Buy Now40.98%Stephens & Co.
Mason Carrico38%
$45 → $45ReiteratesOverweight → OverweightGet Alert
03/20/2025Buy Now40.98%Craig-Hallum
John Wilkin12%
→ $45Initiates → BuyGet Alert
02/25/2025Buy Now53.51%UBS
Lu Li14%
$46 → $49MaintainsBuyGet Alert
02/25/2025Buy Now40.98%Guggenheim
Subbu Nambi35%
$45 → $45ReiteratesBuy → BuyGet Alert
02/25/2025Buy Now59.77%Needham
Mike Matson54%
$51 → $51ReiteratesBuy → BuyGet Alert
01/29/2025Buy Now59.77%Needham
Mike Matson54%
$44 → $51MaintainsBuyGet Alert
12/05/2024Buy Now15.91%Goldman Sachs
Matthew Sykes64%
$38 → $37DowngradeBuy → NeutralGet Alert
11/18/2024Buy Now-12.28%Morgan Stanley
Tejas Savant50%
$26 → $28MaintainsUnderweightGet Alert
11/08/2024Buy Now37.84%Scotiabank
Sung Ji Nam45%
$40 → $44MaintainsSector OutperformGet Alert
11/07/2024Buy Now19.05%Goldman Sachs
Matthew Sykes64%
$34 → $38MaintainsBuyGet Alert
11/07/2024Buy Now44.11%UBS
Lu Li14%
$43 → $46MaintainsBuyGet Alert
11/07/2024Buy Now37.84%Needham
Mike Matson54%
$37 → $44MaintainsBuyGet Alert
10/17/2024Buy Now25.31%Leerink Partners
Puneet Souda58%
$35 → $40MaintainsOutperformGet Alert
10/16/2024Buy Now34.71%UBS
Lu Li14%
→ $43Initiates → BuyGet Alert
10/10/2024Buy Now25.31%Guggenheim
Subbu Nambi35%
→ $40Initiates → BuyGet Alert
08/28/2024Buy Now15.91%Needham
Mike Matson54%
$31 → $37MaintainsBuyGet Alert
08/12/2024Buy Now-18.55%Morgan Stanley
Tejas Savant50%
$21 → $26MaintainsUnderweightGet Alert
08/07/2024Buy Now-2.88%Needham
Mike Matson54%
$27 → $31MaintainsBuyGet Alert
05/08/2024Buy Now-15.41%Needham
Mike Matson54%
$33 → $27MaintainsBuyGet Alert
04/15/2024Buy Now-12.28%Goldman Sachs
Matthew Sykes64%
$32 → $28MaintainsBuyGet Alert
02/26/2024Buy Now-34.21%Morgan Stanley
Tejas Savant50%
$22 → $21MaintainsUnderweightGet Alert
02/23/2024Buy Now3.38%Needham
Mike Matson54%
$30 → $33MaintainsBuyGet Alert
11/10/2023Buy Now-31.08%Morgan Stanley
Tejas Savant50%
$23 → $22MaintainsUnderweightGet Alert
11/08/2023Buy Now-6.02%Needham
Mike Matson54%
$35 → $30MaintainsBuyGet Alert
10/23/2023Buy Now0.25%Goldman Sachs
Matthew Sykes64%
$37 → $32MaintainsBuyGet Alert
10/20/2023Buy Now0.25%Goldman Sachs
Matthew Sykes64%
$37 → $32MaintainsBuyGet Alert
10/10/2023Buy Now6.52%Stephens & Co.
Mason Carrico38%
→ $34ReiteratesOverweight → OverweightGet Alert
08/09/2023Buy Now-27.94%Morgan Stanley
Tejas Savant50%
$22 → $23MaintainsUnderweightGet Alert
08/09/2023Buy Now9.65%Needham
Mike Matson54%
$34 → $35MaintainsBuyGet Alert
05/08/2023Buy Now-6.02%Stephens & Co.
Mason Carrico38%
→ $30Reiterates → OverweightGet Alert
02/23/2023Buy Now6.52%Needham
Mike Matson54%
$33 → $34MaintainsBuyGet Alert
01/18/2023Buy NowRaymond James
Andrew Cooper54%
DowngradeOutperform → Market PerformGet Alert
01/05/2023Buy Now3.38%Scotiabank
Sung Ji Nam45%
→ $33Initiates → Sector OutperformGet Alert
11/04/2022Buy Now-31.08%Morgan Stanley
Tejas Savant50%
$23 → $22MaintainsUnderweightGet Alert
11/04/2022Buy Now-15.41%Raymond James
Andrew Cooper54%
$31 → $27MaintainsOutperformGet Alert
11/03/2022Buy Now3.38%Needham
Mike Matson54%
$31 → $33MaintainsBuyGet Alert
11/03/2022Buy Now9.65%SVB Leerink
Puneet Souda58%
$30 → $35MaintainsOutperformGet Alert
08/04/2022Buy Now-2.88%Raymond James
Andrew Cooper54%
$30 → $31MaintainsOutperformGet Alert
08/03/2022Buy Now-2.88%Needham
Mike Matson54%
$26 → $31MaintainsBuyGet Alert
05/05/2022Buy Now-6.02%Stephens & Co.
Mason Carrico38%
$44 → $30MaintainsOverweightGet Alert
05/04/2022Buy Now-27.94%Morgan Stanley
Tejas Savant50%
$25 → $23MaintainsUnderweightGet Alert
05/04/2022Buy Now-6.02%Raymond James
Andrew Cooper54%
$34 → $30MaintainsOutperformGet Alert
05/04/2022Buy Now-18.55%Needham
Mike Matson54%
$31 → $26MaintainsBuyGet Alert

FAQ

Q

What is the target price for Veracyte (VCYT) stock?

A

The latest price target for Veracyte (NASDAQ:VCYT) was reported by Guggenheim on April 9, 2025. The analyst firm set a price target for $37.00 expecting VCYT to rise to within 12 months (a possible 15.91% upside). 20 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Veracyte (VCYT)?

A

The latest analyst rating for Veracyte (NASDAQ:VCYT) was provided by Guggenheim, and Veracyte maintained their buy rating.

Q

When was the last upgrade for Veracyte (VCYT)?

A

There is no last upgrade for Veracyte

Q

When was the last downgrade for Veracyte (VCYT)?

A

The last downgrade for Veracyte Inc happened on December 5, 2024 when Goldman Sachs changed their price target from $38 to $37 for Veracyte Inc.

Q

When is the next analyst rating going to be posted or updated for Veracyte (VCYT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Veracyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Veracyte was filed on April 9, 2025 so you should expect the next rating to be made available sometime around April 9, 2026.

Q

Is the Analyst Rating Veracyte (VCYT) correct?

A

While ratings are subjective and will change, the latest Veracyte (VCYT) rating was a maintained with a price target of $45.00 to $37.00. The current price Veracyte (VCYT) is trading at is $31.92, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch